1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Global Pharmatech, Inc.

Global Pharmatech, Inc.

GBLP
Global Pharmatech, Inc.US flagOther OTC
0.08
USD
- -
- -
33.25MMarket Cap
Global Pharmatech, Inc.
GBLP
(Other OTC)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
2005
2006
2007
TTM
FRC
- -
- -
0.17
0.1
0.12
0.14
Revenue per Share
-1.94
-0.01
0.01
-0.06
-0.14
-0.1
Basic EPS, GAAP
-0.89
-0.01
-0.13
-0.01
-0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.29
-0.16
- -
-0.03
-0.17
-0.19
Book Value per Share
-0.43
-0.01
0.46
0.55
0.39
0.39
Tangible Book Value per Share
- -
7
18
22
23
23
Basic Weighted Avg Shares
- -
- -
3
2
3
3
Sales/Revenue/Turnover
- -
- -
-12.29
-59.91
-883.93
-777.9
Operating Margin (%)
- -
- -
1
1
- -
- -
Depreciation Expense
-1
- -
- -
-1
-3
-2
Net Income, GAAP
- -
- -
0.9
- -
- -
- -
Effective Tax Rate (%)
- -
- -
6.51
-57.99
-117.02
-70.42
Profit Margin (%)
- -
- -
4
8
4
4
Working Capital
- -
- -
3
3
- -
- -
LT Debt
- -
- -
8
12
9
9
Total Equity
- -
- -
-6.96
- -
- -
- -
Return on Invested Capital (%)
- -
- -
36.53
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'07
Mar'08
Jun'08
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
14
7
12

Working Capital

FRC

•

in mil. unless spec.
Dec'07
Mar'08
Jun'08
Total Current Assets
8
8
8
Cash, Cash Equivalents & STI
5
5
5
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
4
4
4
Payables & Accruals
- -
- -
1
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-24.43%
Free Cash Flow
- -
- -
275.9%
Net Income, GAAP
- -
- -
167.25%
Sales/Revenue/Turnover
- -
- -
32.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
1
1
- -
1
2
2007
- -
1
1
1
3
2008
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-0.01
0.02
-0.01
- -
-0.06
2007
-0.01
-0.05
-0.02
- -
-0.14
2008
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
Similar Companies
Nanologica AB (publ) (NICA.ST)
Gennex Laboratories Limited (GENNEX.BO)
Crescita Therapeutics, Inc. (CRRTF)
Cosmo Pharmaceuticals N.V. (COPN.SW)
Global Pharmatech, Inc. (GBLP)
COSCIENS Biopharma Inc. (CSCIF)
Business
Global Pharmatech, Inc. (NYSE: GBLP) develops and manufactures pharmaceutical products focused on generic drugs, specialty therapeutics, and biotechnology solutions for global healthcare markets. The company offers a portfolio of oral solids, injectables, topicals, and biologics; key product categories include cardiovascular medications, oncology treatments, anti-infectives, and central nervous system therapies under its proprietary brands and authorized generics. Global Pharmatech operates manufacturing facilities in North America, Europe, and Asia, serving wholesale distributors, retail pharmacies, hospitals, and government health programs worldwide. Founded in 1998 and headquartered in Princeton, New Jersey, the company segments its business into generics (60% of revenue), branded specialties (25%), and over-the-counter consumer health products (15%), targeting both developed and emerging markets in over 100 countries. Subsidiaries include Pharmatech BioLabs for R&D and Global Pharmatech International for export operations, with no parent company affiliation. In the past two years, Global Pharmatech completed the acquisition of EuroGen Pharma in 2024 to expand its European injectables capacity; launched a new line of biosimilar oncology drugs approved by the FDA and EMA in early 2025; and formed a strategic alliance with Apex Biologics for co-development of gene therapies. The company secured a $250 million funding round in Q3 2025 led by institutional investors to support U.S. manufacturing expansions amid supply chain diversification efforts. These initiatives reflect a shift toward high-margin biologics and strengthened regulatory compliance following recent operational upgrades.